Andes Biotechnologies

Andes Biotechnologies S.A. is a biotechnology company based in Santiago, Chile, focused on the research, development, and marketing of innovative anti-cancer therapies in the United States and Europe. Founded in 2010, the company specializes in nucleic acid-based drug discovery, particularly targeting solid tumor cancers. It has developed proprietary technology utilizing long non-coding RNAs, specifically sense (S-RNA) and antisense (AS-RNA), which are synthesized in mitochondria and migrate to the nucleus. These oligonucleotide drugs selectively induce apoptosis in cancer cells, leaving normal cells unharmed. Andes Biotechnologies is currently advancing its lead drug, Andes-1537, through clinical development and holds an active investigational new drug (IND) application in the United States. The company is supported by an experienced management team and a strong network of collaborators in the cancer research field, along with a comprehensive intellectual property portfolio.